TrialThe Journal of infectious diseases2013

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Joseph J Eron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.